Company Overview of Foresight Biotherapeutics, Inc.
Foresight Biotherapeutics, Inc. develops treatments and therapies to address unmet needs in ophthalmology and otolaryngology. Its products include FST-100 for the clinical needs of microbial eradication and reduction in inflammation associated with ocular infections, as well as for adenoviral conjunctivitis; and FST-201, a topical formulation of povidone-iodine and dexamethasone for the treatment of acute otitis media. The company was incorporated in 2008 and is based in New York, New York. As of July 30, 2015, Foresight Biotherapeutics, Inc. operates as a subsidiary of Shire plc.
50 West 57th Street
New York, NY 10019
Founded in 2008
Key Executives for Foresight Biotherapeutics, Inc.
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Foresight Biotherapeutics, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.